Clinical trial · Observational
A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
A Prospective, Multicenter, Exploratory Clinical Study Evaluating the Application of Tissue-Agnostic Technology in the Dynamic Monitoring of Minimal Residual Disease in Stage III Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study aims to evaluate the predictive performance of various omics-based methods for detecting minimal residual disease (MRD) in stage III colorectal cancer. The study involves the collection of blood samples from patients who have accepted surgery for colorectal cancer. Blood samples will be analyzed using both tumor-informed and tumor-agnostic approaches to detect circulating tumor DNA (ctDNA). The study will compare the sensitivity of these methods and assess their correlation with recurrence risk. The findings aim to inform the development of optimal MRD detection strategies, ultimately providing a robust molecular basis for personalized treatment decisions.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| ctDNA | — | UNRESOLVED | — |
| MRD | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRD detection | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with stage III colorectal cancer
- interventionNames
- Diagnostic Test: MRD detection
Primary outcomes (1)
- measure
- The predictive role of MRD in prognosis
- timeFrame
- 3 years
- description
- The survival difference between MRD positive and MRD negative patients.
Secondary outcomes (2)
- measure
- The positive detection rate of baseline ctDNA
- timeFrame
- 1 year
- measure
- Predictive Accuracy of MRD for Recurrence
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Histologically confirmed colorectal cancer. * Preoperatively assessed as stage III according to the 8th edition UICC/AJCC staging system. * Deemed eligible for radical resection upon investigator assessment. * No prior anti-tumor therapy received. * ECOG PS score 0-1. * Willing and able to provide signed informed consent for participation in the study. Exclusion Criteria: * Has a history of other malignant tumors. * Pregnant and lactating women. * Presence of any concurrent medical or psychiatric condition, as assessed by the investigator, that may interfere with protocol compliance, study follow-up, or affect short-term survival.
References
Publications (0)
Data not yet available